To evaluate the safety profile and potential on-target, off-tumor effects of the CEA TCB Cibisatamab, we expanded our 3D-RDL assay to include healthy organoid models, specifically rectal and small intestinal organoids. This evidence concerns the gene CEACAM3 and neoplasm.